Natural Alternatives International (NASDAQ:NAII) and Kenvue (NYSE:KVUE) Financial Contrast

Kenvue (NYSE:KVUE) and Natural Alternatives International (NASDAQ:NAII) are both consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.

Profitability

This table compares Kenvue and Natural Alternatives International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kenvue	10.76%	21.22%	8.37%
Natural Alternatives International	-10.13%	-12.21%	-5.30%

Valuation & Earnings

This table compares Kenvue and Natural Alternatives International”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kenvue	$15.12 billion	2.44	$1.47 billion	$0.87	22.10
Natural Alternatives International	$129.86 million	0.10	-$13.57 million	($2.39)	-0.91

Kenvue has higher revenue and earnings than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Kenvue, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Kenvue has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.

Insider & Institutional Ownership

97.6% of Kenvue shares are owned by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are owned by institutional investors. 1.6% of Kenvue shares are owned by insiders. Comparatively, 20.8% of Natural Alternatives International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Kenvue and Natural Alternatives International, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kenvue	0	12	3	0	2.20
Natural Alternatives International	1	0	0	0	1.00

Kenvue presently has a consensus target price of $19.27, suggesting a potential upside of 0.22%. Given Kenvue’s stronger consensus rating and higher probable upside, equities analysts clearly believe Kenvue is more favorable than Natural Alternatives International.

Summary

Kenvue beats Natural Alternatives International on 13 of the 14 factors compared between the two stocks.

About Kenvue

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

About Natural Alternatives International

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.